Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
Status:
Completed
Trial end date:
2016-04-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the influence of dose selection of CPT-11 on
toxicity, response and pharmacokinetics according to UGT1A1 genotype in colorectal cancer
patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences